Determination of the frequency of mutations of Mycobacterium tuberculosis against the compound tris-(1.10-phenanthroline)iron(II) and in vivo bioavailability studies

• Grant number: 17/12419-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: September 01, 2017
• End date: August 31, 2018
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Fernando Rogério Pavan
• Grantee: Caio Sander Paiva Silva
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Tuberculosis is a disease caused by Mycobacterium tuberculosis. According to World Health Organization, 10.4 million new cases of tuberculosis were estimated in 2015, of which 480,000 are multidrug-resistant. Compared with previous years, the increase in resistant infections is noteworthy, leading to the need for new drugs. As the object of this project we will study the tris-(1.10-phenanthroline)iron(II) compound that represents a candidate for a new drug against tuberculosis, with promising studies in vitro in our laboratory. This project aims to determine the frequency of spontaneously resistant bacteria and to study them comparatively with other antibiotics used in the therapy in the search for a possible mechanism of action. In addition, in vivo assays will be performed to assess the oral bioavailability of the compound and the possible toxicity generated by it. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SOLCIA, MARIANA CRISTINA; CAMPOS, DEBORA LEITE; GRECCO, JULIA ARAUJO; PAIVA SILVA, CAIO SANDER; DA SILVA, PATRICIA BENTO; DA SILVA, ISABEL CRISTIANE; BALDUINO DA SILVA, ANA PAULA; SILVA, JOAS; ODA, FERNANDO BOMBARDA; DOS SANTOS, ANDRE GONZAGA; et al. rowth-inhibitory effects of tris-(1,10-phenanthroline) iron (II) against Mycobacterium tuberculosis in vitro and in viv. TUBERCULOSIS, v. 128, MAY 2021. (20/13497-4, 18/12270-6, 17/12419-7, 16/24633-0, 18/21778-3, 18/12135-1, 18/00163-0)

DE SOUZA, P. C.; FERNANDES, G. F. S.; MARINO, L. B.; RIBEIRO, C. M.; DA SILVA, P. B.; CHORILLI, M.; SILVA, C. S. P.; RESENDE, F. A.; SOLCIA, M. C.; DE GRANDIS, R. A.; et al. Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection. BIOMEDICINE & PHARMACOTHERAPY, v. 130, OCT 2020. (18/11079-0, 18/00163-0, 14/03920-6, 17/12419-7, 16/09502-7, 14/02240-1, 13/14957-5, 16/02860-5, 14/24811-0, 16/24633-0, 18/17739-2, 15/19531-1, 16/22429-7, 14/11586-9)

SOLCIA, MARIANA CRISTINA; CAMPOS, DEBORA LEITE; GRECCO, JULIA ARAUJO; PAIVA SILVA, CAIO SANDER; DA SILVA, PATRICIA BENTO; DA SILVA, ISABEL CRISTIANE; BALDUINO DA SILVA, ANA PAULA; SILVA, JOAS; ODA, FERNANDO BOMBARDA; DOS SANTOS, ANDRE GONZAGA; et al. Growth-inhibitory effects of tris-(1,10-phenanthroline) iron (II) against Mycobacterium tuberculosis in vitro and in vivo. TUBERCULOSIS, v. 128, p. 8-pg., 2021-05-19. (18/00163-0, 16/24633-0, 18/21778-3, 17/12419-7, 18/12270-6, 18/12135-1, 20/13497-4)